On 20 November 2018, the European Haemophilia Consortium (EHC) held its third and last Round Table of Stakeholders of the year at the European Parliament in Brussels. The event focused on ‘Switching from Standard Therapies: Where do Novel Therapies fit in?’ and was kindly hosted by Member of the European Parliament (MEP) Cristian Silviu Bușoi (EPP, Romania) and attended by MEPs Dr Miroslav Mikolášik (EPP, Slovakia).
This event focused on the arrival of novel therapies, both extended half-life and non-replacement therapies, on the European market and looked at crucial issues such as patient selection criteria, personalisation of treatment and economic appraisal and access to these medicines. Participants then heard real-life experiences in switching patients to novel therapies in Ireland and France as well as a call for ensuring access to novel therapies in countries with limited resources such as Romania.
Below, you can consult the agenda, speakers’ biographies, presentations and other documents provided during the Round Table. Pictures from the event are on our Facebook page.